I think, ultimately, the big issue for many will be what happens in the United States if we hear about people who didn't go to China who have come down with the disease.
Gilead offers a nearly 4% yield and looks ready to return to growth.
Stemline Therapeutics, Entercom Communications and Ocular Therapeutix offer reasons to think their shares will perform better in the New Year.
Let's review the charts of Allakos and Global Blood Therapeutics.
Sharp drops in Heron Therapeutics and Supernus Pharmaceuticals have presented opportunities to make lemonade out of lemons.
The market may need some rest and consolidation, but that doesn't mean it will produce a lot of downside.
Shares of Replimune Group and Eyenovia have swung up and down in 2019 but should be on the rise next year.
Like Karuna, Sage Therapeutics and Intra-Cellular Therapies also deal in treatments in the mental health arena.
Shares of Stemline Therapeutics and Entercom Communications headed opposite directions last Friday after reporting results.
Karyopharm Therapeutics and Pieris Pharmaceuticals are climbing this week on positive news, while Supernus Pharmaceuticals takes a hit.